Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Simtuzumab in IPF
NCT01759511Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2012
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), sponsored by Gilead Sciences. Started Oct 2012; status: terminated.
02
Drugs
simtuzumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01759511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01759511.